Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828891 | 1.00 | NAMPT (0.57) | NAMPTAKT1 | |
| SCHEMBL23828880 | 0.84 | NAMPT (0.52) | NAMPT | |
| SCHEMBL2378017 | 0.78 | NAMPT (0.55) | NAMPT | |
| SCHEMBL30452486 | 0.78 | NAMPT (0.52) | NAMPT | |
| SCHEMBL23828924 | 0.78 | NAMPT (0.52) | NAMPT | |
| SCHEMBL23291127 | 0.75 | AKT1 (0.53) | NAMPTAKT1 | |
| SCHEMBL12162569 | 0.73 | MAPK1 (0.53) | NAMPT | |
| SCHEMBL31646737 | 0.71 | NAMPT (0.52) | NAMPT | |
| SCHEMBL379892 | 0.71 | CA2 (0.54) | NAMPT | |
| SCHEMBL3868210 | 0.71 | CA2 (0.54) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814355-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| CN-111164084-B | Triazolotriazine derivatives useful as A2A receptor antagonists | 浙江春禾医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | NAMPT 1862/4885AKT1 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.